Back to Journals » International Journal of Nanomedicine » Volume 6

Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles

Authors Chen Y, Wan Y, Wang Y, Zhang H, Jiao Z

Published 18 October 2011 Volume 2011:6 Pages 2321—2326


Review by Single anonymous peer review

Peer reviewer comments 2

Yan Chen1,*, Ying Wan1,*, Yi Wang1, Haijun Zhang2, Zhijun Jiao1
Key Laboratory of Medical Immunology and Department of Laboratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang; 2Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China
*These authors have contributed equally to this work

Background: Doxorubicin has a broad spectrum of anticancer activity, but its clinical application is limited due to serious side effects. The aim of this study was to explore a novel drug delivery system based on titanium dioxide (TiO2) nanoparticles for its potential role in enhancing the anticancer efficacy of doxorubicin while reducing its side effects.
Methods and results: Doxorubicin was loaded into TiO2 nanoparticles by forming complexes with the transition metal, titanium, to construct doxorubicin-titanium dioxide (DOX-TiO2) nanocomposites as a drug delivery system. The anticancer activity of the DOX-TiO2 nanocomposites was demonstrated by MTT assay, and the possible signaling pathway was explored by Western blot. In human SMMC-7721 hepatocarcinoma cells, our observations demonstrated that this drug delivery system markedly increased the efficiency of drug per dosage and decreased the IC50, resulting in anticancer efficacy enhancement and side effect attenuation.
Conclusion: Such a doxorubicin delivery strategy is promising in cancer therapy. Apoptosis may contribute to the mechanism, due to protein expression of Bcl-2 being downregulated and that of Bax and caspase 3 being upregulated.

Keywords: doxorubicin, titanium dioxide nanoparticles, drug delivery system, apoptosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]